Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn's disease
Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn's disease
复制标题
DOI：
10.1023/b:ddas.0000042246.58984.98
复制
发表时间：
2004-09-01
影响因子：
3.1
通讯作者：
Mahl, TC
中科院分区：
文献类型：
--
作者：
Kaur, N;Mahl, TC
Anti-tumor necrosis factor-α antibody, infliximab, has become an established effective therapy for Crohn’s disease and rheumatoid arthritis. In each disease, this medication is usually reserved for patients who fail to respond to conventional therapy (1). The use of infliximab as a therapy for other autoimmune diseases including sarcoidosis, psoriasis, ankylosing spondylitis, and arthritis has been suggested (2). While this therapy is helpful to many who suffer from inflammatory disease, it is not without hazard. Infliximab has been associated with invasive aspergillosis (3), histoplasmosis (4), cytomegalovirus (5), listeriosis (6, 7), and tuberculosis reactivation (8). There have been reports of drug-induced lupus secondary to infliximab therapy (9). Retinal vein thrombosis and new-onset heart failure have also been reported in association with this medication (10, 11). In 2002, Taiet al. reported a case ofPneumocystis carinii pneumonia (PCP) in a patient receiving infliximab for rheumatoid arthritis (12); the US Food and Drug Administration has 10 reports on file of patients developing PCP after infliximab infusion (13). Although PCP after infliximab therapy for Crohn’s disease has been mentioned in reviews (14), no formal cases have yet been reported. Here we report a case of PCP with oral candidiasis after a second infusion of infliximab for Crohn’s disease.
